Vec­tor Bio­Med launch­es with $15M to pro­duce back­logged CAR-T com­po­nent

The man­u­fac­ture of lentivi­ral vec­tors has been grab­bing the at­ten­tion of in­vestors both small and large as of late, and an­oth­er man­u­fac­tur­er is look­ing to jump on­to the scene.

Vec­tor Bio­Med, a Mary­land-based bio­man­u­fac­tur­ing com­pa­ny, has raised $15 mil­lion, ac­cord­ing to CEO Boro Drop­ulić in an in­ter­view with End­points News. The im­pe­tus be­hind the com­pa­ny, Drop­ulić said, is for Vec­tor Bio­Med to fill a gap in the de­mand and ac­cess to lentivi­ral vec­tors, a key com­po­nent in CAR-T ther­a­pies and oth­er treat­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER